Pharmaceutical development for treating pancreatic diseases

Pancreas

Volumn 16, Issue 3, 1998, Pages 427-431

  Kitagawa, Motoji ^a   Naruse, Satoru ^a   Ishiguro, Hiroshi ^a   Hayakawa, Tetsuo ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antibiotics; CCK receptor antagonist; Pancreatitis; Protease inhibitor; Somatostatin

Indexed keywords

ANTIBIOTIC AGENT; CAMOSTAT; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DEVAZEPIDE; EDETATE CALCIUM DISODIUM; ENZYME; GABEXATE MESILATE; LORGLUMIDE; LOXIGLUMIDE; NAFAMSTAT MESILATE; PANCREAS ENZYME; PROGLUMIDE; PROTEINASE INHIBITOR; SOMATOSTATIN; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TRIMETHADIONE;

ACUTE PANCREATITIS; CHRONIC PANCREATITIS; ENZYME REPLACEMENT; EXTRACORPOREAL LITHOTRIPSY; INFECTION; PANCREAS DISEASE; PANCREAS STONE; PRIORITY JOURNAL; REVIEW;

EID: 0031897012     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199804000-00035     Document Type: Review

References (31)

1. Steinberg W, Tenner A. Medical progress. Acute pancreatitis. N Engl J Med 1994;330:1198-210.
2. Lumsden A, Bradley EL III. Secondary pancreatic infections. Surg Gynecol Obstet 1990;170:459-67.
3. Barie PS. A critical review of antibiotic prophylaxis in severe acute pancreatitis. Am J Surg 1996;172(suppl 6A):38-43S.
4. Delcenserie R, Yzet T, Ducroix JP. Prophylactic antibiotics in treatment of severe acute alcoholic pancreatitis. Pancreas 1996; 13:198-201.
5. Pederzoli P, Bassi C, Vesentini S. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol Obstet 1993;176:480-3.
6. Baxter JN, Imrie CW, MaKay CJ. Acute pancreatitis and octreotide. Lancet 1991;338:389.
7. Buchler M. Malfertheiner P, Uhl W, et al. Gabexate mesilate in human acute pancreatitis. Gastroenterology 1993;104:1165-70.
8. Messori A, Rampazzo R, Scroccaro G. et al. Effectiveness of gabexate mesilate in acute pancreatitis: a meta-analysis. Dig Dis Sci 1995;40:734-8.
9. Harada H, Miyake H, Ochi K, Tanaka J, Kimura I. Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis. Int J Pancreatol 1991;9:75-9.
10. Pasricha P. Prevention of ERCP-induced pancreatitis: success at last. Gastroenterology 1997;112:1415-22.
11. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariani A, Di Francesco V, the Gabexate in Digestive Endoscopy Italian group. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. N Engl J Med 1996;335:919-23,
12. Muto S, Imai M, Asano Y. Mechanisms of hyperkalemia caused by nafamostat mesilate. Gen Pharmacol 1995;26:1627-32.
13. Takeda K, Matsuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg 1996;171:394-8.
14. Sobajima H, Hayakawa T, Kondo T, et al. Monitoring serum tryptic activity and effect of trypsin inhibitor on rat acute pancreatitis. Digestion 1994;55:90-6.
15. Aho H, Nevalainen T, Lindberg R, Aho A. Experimental pancreatitis in rat: the role of phospholipase A in sodium taurocholate-induced acute haemorrhagic pancreatitis. Scand J Gastroenterol 1980;15:1027.
16. 2EDTA, a phospholipase A inhibitor, in the management of human acute pancreatitis. Scand J Gastroenterol 1995;20:5.
17. 2 in serum samples from patients with severe acute pancreatitis. Gut 1993;34:1133-6.
18. Niederau C, Liddle RA, Ferrell LD, Grendell JH. Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice: evidence for cholecystokinin as a major factor in the development of acute pancreatitis. J din Invest 1986;78:1056-63.
19. Gomez G, Townsend CM Jr, Green DW, et al. Protective action of luminal bile salts in necrotizing acute pancreatitis in mice. J Clin Invest 1990;86:323-31.
20. Oshiro G, Saluja A, Leli U, Sengupta A, Steer ML. Failure of a potent cholecystokinin antagonist to protect against diet-induced pancreatitis in mice. Pancreas 1989;6:739-43.
21. Nakano S, Tachibana I, Otsuki M. Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis. Pancreas 1995;10:287-94.
22. Kingsnorth A. Role of cytokines and their inhibitors in acute pancreatitis. Gut 1997;40:1-4.
23. Scholmerich J. Interteukins in acute pancreatitis. Scand J Gastroenterol 1996;31(suppl 219):37-42.
24. Kingsnorth AN, Galloway SW, Formela LJ. Randomized, double-blind phase II trial of lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg 1995;82:1414-20.
25. Kanoh M, Ibata H, Miyagawa M, Matsuo Y. Clinical effects of camostat in chronic pancreatitis. Biomed Res 1989;10(suppl 1): 145-50.
26. Harada H, Ishibashi T, Ochi K, et al. Effect of chronic administration of a protease inhibitor camostat on secretion of pure human pancreatic juice. Biomed Res 1989;10(suppl 1):63-9.
27. Steer ML, Waxman I, Freedman S. Medical progress: chronic pancreatitis. N Engl J Med 1995;332:1482-90.
28. Delhaye M, Menus S, Gohimont AC, Buedts K, Cremer M. Comparative evaluation of a high lipase pancreatic enzyme preparation and a standard pancreatic supplement for treating exocrine pancreatic insufficiency in chronic pancreatitis. Eur J Gastroenterol Hepatol 1996;8:699-703.
29. Sauerbruch T, Holl J, Sackmann M, et al. Extracorporeal shock wave lithotripsy of pancreatic stones. Gut 1989;30:1406-11.
30. Ohara H, Hoshino M, Hayakawa T, et al. Single application extracorporeal shock wave lithotripsy is the first choice for patients with pancreatic duct stones. Am J Gastroenterol 1996;91:1388-94.
31. Noda A, Okuyama M, Murayama H, et al. Dissolution of pancreatic stones by oral trimethadione in patients with chronic calcific pancreatitis. J Gastroenterol Hepatol 1994;9:478-85.